DAX+1,64 % EUR/USD+0,89 % Gold-0,77 % Öl (Brent)+0,47 %

Evolva langfristig sehr interessant!!!!!

ISIN: CH0021218067 | WKN: A0EAKH | Symbol: ADF
0,373
02.12.16
Tradegate
-2,10 %
-0,008 EUR

Neuigkeiten zur Evolva Holding Aktie


Beitrag schreiben
Antwort auf Beitrag Nr.: 51.576.384 von heyhope am 25.01.16 21:30:02ich bin dabei seit der KE wo der Kurs bei 0.60 stand. das auf und ab ist normal bei evolva. doch der letzte rücksetzter war ein bisschen heftig:-)
Nun gut, wenn die PRodukte funktionieren und evolva in paar jahren gewinn schreibt, geht der kurs durch die decke:-)
auf WO ist evolva wohl keine diskusion wert:-)
Antwort auf Beitrag Nr.: 51.577.764 von deam85 am 26.01.16 07:21:58Ich bin Seit April 2015 dabei. KE auch mitgemacht und den Rücksetzer genutzt, um Einstandskurs zu drücken.

Vorallem Stevia und Kooperation mit Cargrill ist sehr interessant.

Eine Perle im biotech Bereich.
Antwort auf Beitrag Nr.: 51.577.833 von heyhope am 26.01.16 07:41:43ja mit 1.40 warst du ziemlich hoch. jetzt bist du immerhin bei 1.10.
klar sehr interessant. aber das musst erst mal alles früchte tragen....
13 July 2016 – Evolva (SIX: EVE) announces that its resveratrol compound will be part of a female reproductive health study conducted at the Poznan University of Medical Sciences in Poznan, Poland. The aim of this randomised, double-blind, placebo-controlled clinical trial is to examine endocrine and metabolic effects from the combined use of the statin simvastatin and resveratrol for women suffering from Polycystic Ovary Syndrome (PCOS). Globally, PCOS is considered the leading cause of female infertility. PCOS symptoms also include ovarian cysts, acne, obesity, baldness, pelvic pain, anxiety, depression and sleep apnea. Resveratrol is a compound found in red grapes, blueberries, nuts and other plants. There is already a significant body of evidence showing that resveratrol can produce a positive impact on healthy-ageing variables like heart health, bone health, and blood-glucose control. Scientists have also found evidence that resveratrol had a positive effect on key biomarkers related to slowing the progression of Alzheimer’s disease in addition to mimicking the age decelerating results of a calorie-restricted diet. Evolva’s resveratrol comes from a unique fermentation source which produces a pure compound free of any environmental contaminants. In recent years, statins like simvastatin have become a novel therapeutic approach to PCOS. Studies on isolated ovarian theca-interstitial cells indicate that resveratrol can reduce the production of androgens. (Though commonly known as “male hormones”, women produce androgens, too.) Elevated levels of androgens are symptomatic of PCOS. The clinical trial will evaluate whether this novel combination therapy can lead to enhanced therapeutic benefits for those suffering from PCOS. The study will enroll 60 women between the ages of 18 and 45. It will compare a daily combination therapy of 20 mg simvastatin and 500 mg resveratrol with a single 20 mg dose of simvastatin. Endocrinological, hormonal and biochemical evaluations will be performed at baseline and repeated after 3 and 6 months of treatment. Poznan University of Medical Sciences is the sponsor of this study, with collaboration from the University of California, San Diego. - See more at: http://www.evolva.com/press-release/evolvas-resveratrol-part-of-novel-combination-therapy-to-be-tested-in-a-clinical-trial-for-women-with-polycystic-ovary-syndrome/#sthash.TNU4oZGp.dpuf


Beitrag zu dieser Diskussion schreiben